Small Hospitals
Market Cap
₹6,236 ₹6,236 Cr.
P/E
81.16
PEG
2.50
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive only if planned treatment-volume growth converts from new and acquired capacity; capacity additions alone do not create revenue in this fixed-capacity business.

Bull path depends on a faster treatment-volume ramp combined with a stronger revenue-per-treatment mix, while bear path is triggered by treatment-volume underperformance alongside stagnant revenue per treatment.

Key revision triggers to watch include quarterly treatment growth, revenue per treatment, clinic additions, and the Andhra Pradesh PPP renewal outcome.

Key Ratios

Debt to Equity
Debt to Equity
0.02
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
6.41 %
Institutions
Institutions
19.84 %
Market cap
Market cap
6,236 Cr
No. of Shareholders
No. of Shareholders
56,735
OPM (%)
OPM (%)
21.85 %
PE
PE
81.16
Prom Holding
Prom Holding
58.31 %
ROCE (%)
ROCE (%)
14.14
ROE (%)
ROE (%)
6.88
Sales
Sales
1,034 Cr
  • Nephrocare Health
  • Narayana Hrudayalay.
  • Jupiter Life Line
Last updated on 28 Sep 2026
  • NephroPlus runs ~550 dialysis clinics, mostly in India. Dialysis services are ~85% of revenue within a single reportable segment, with related healthcare products the balance.
  • End-markets are government, PPP and private payors in India, the Philippines and Uzbekistan, where the Ministry of Health is the payor. International is ~45% of revenue.
  • It was almost entirely India-based in FY23, with international at 11.7% of revenue. Acquisitions and new-country entries have taken international to ~45%.
  • Growth comes from 40–50 new India clinics a year, an acquisition-led Philippines roll-up, and Uzbekistan's government-payor model. Saudi Arabia and Kazakhstan are early platforms.
  • India Ratings upgraded it to IND AA-/Stable in September 2026, citing over half of India's organized dialysis market, recurring demand and net cash.
  • Management guides 15–20% revenue growth over the next 3–5 years and a new international market every 12–18 months, with return thresholds screening capital.
  • Q1FY27 adjusted EBITDA margin of 23.1% was below FY26's 23.8%. Management says part of the year-on-year improvement was a one-off utilization benefit.
  • Working capital stays heavy on 3–4 month government collection cycles. IPO-funded India clinic capex is behind plan, with ₹116.3Cr of ₹129.1Cr unutilised at June.
  • Growth is capacity-addition-led, with network utilization at about 74%. Saudi Arabia remains a pre-scale, binary option with unguided losses.
  • The Uzbekistan unit faces a ₹14.79Cr tax order on its dialysis-income exemption, about 1.5% of FY26 revenue. The company disputes the order.
  • Uzbekistan tax dispute late Sep 2026 onward
    the ₹14.79Cr order tests the >90% dialysis-income tax exemption. Any provisioning would show at Q2FY27 results.
  • Saudi Arabia dialysis tender tender expected in ~2 months
    an award decides whether the 51% dialysis joint venture scales. Management sees 3–4 quarters to full clarity.
  • Andhra Pradesh PPP dialysis contract renewal late CY2026
    renewal terms will set pricing and volumes for an existing government dialysis contract.
  • Philippines dialysis-center roll-up next 12 months
    assets transfer under provisional purchase agreements against a 10–15 clinics/year guide, with no operating contribution filed yet.
  • Kazakhstan dialysis-center acquisition no stated timeline
    completion requires state re-registration in Kazakhstan. The target runs 34 machines with ~₹10.93Cr CY25 turnover.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
446
52W Range
High
782
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Revenue Per Treatment (Rs)
    • Annual Treatments (Million No)
    • Total Number of Clinics

    Peer Comparison

    FAQs on Nephrocare Health Services Ltd. Business

    Nephrocare Health Services is engaged in offering comprehensive dialysis care through its network of clinics - from diagnosis to treatment and wellness programs including haemodialysis, home and mobile dialysis, supported by pharmacy. Its widespread presence ensures patients have easy accessibility to dialysis services.

    Nephrocare Health major competitors are Narayana Hrudayalay., Jupiter Life Line, RainbowChildrenS Med, Dr. Agarwal's Health, Dr. Lal Pathlabs, Metropolis Health., Vijaya Diagnostic.
    Market Cap of Nephrocare Health is ₹6,507 Crs.
    While the median market cap of its peers are ₹14,713 Crs.

    Nephrocare Health seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Feb May Aug
    Investor Presentation Feb May Aug
    Conference Call Feb May Aug
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    []
    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material